Post-earnings recap
Reported
Thu, Feb 27, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Denali Therapeutics reported a loss of $0.56 per share, which did not meet any consensus expectations as revenue figures were not disclosed. The stock fell by 12.07% following the earnings report, likely due to the lack of financial guidance and clarity on future performance. Investors may be concerned about the company's direction without specific revenue targets or updates on their pipeline progress.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.56 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed a commitment to their research and development efforts. They acknowledged the challenges faced but did not provide detailed insights into future performance.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on advancing their pipeline despite the current financial results.